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Abstract
Hydroxy acid oxidase 2 (HAO2) has been reported to inhibit tumor progression
through metabolic pathway. The current study was designed to evaluate the
prognostic significance and probable mechanism of HAO2 in patients with clear cell
renal cell carcinoma (ccRCC). The study screened The Cancer Genome Atlas Kidney
Clear Cell Carcinoma (TCGA‐KIRC) database for patients with ccRCC having
complete clinical information and HAO2 expression. Low HAO2 was associated with
shorter overall survival (OS) and shorter disease‐free survival (DFS). Gene set
enrichment analysis (GSEA) showed HAO2 was associated with neutral lipid catabolic
process, metabolic process, lipid oxidation, epithelial–mesenchymal transition (EMT),
and Kirsten rat sarcoma viral oncogene signaling (KRAS). Western blot analysis and
immunohistochemistry analysis checked HAO2 expression in ccRCC cancer tissues,
normal tissues, and renal cancer cell lines. HAO2 was downregulated in ccRCC cancer
tissues and ccRCC cell lines when compared with their control group. Overexpression
of HAO2 by plasmid promoted lipid catabolic process, eliminated lipid accumulation,
inhibited KRAS expression, controlled the proliferation, migration, and invasion
activity of ccRCC tumor cells. Our results indicated that HAO2 inhibits malignancy
ccRCC by promoting lipid catabolic process, HAO2 could be an effective molecular
marker and treatment for ccRCC.
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1 | INTRODUCTION
Renal cell carcinoma (RCC) is one of the common lethal
malignancy in urology with about 403,262 (2.2%) new cases and
175,098 (1.8%) deaths worldwide among all cancers in 2018
(Bray et al., 2018) and estimated about 73,820 new cases
and 14,770 deaths for United States in 2019 (Siegel, Miller, &
Jemal, 2019). The incidence of RCC has increased gradually in the
past two decades and 30% patients already have cancer
metastasis when they are diagnosed with RCC (Bhatt & Finelli,
2014; Linehan, 2012). Clear cell RCC (ccRCC) is a lethal disease
and accounts for most RCC cancer‐related deaths (Hsieh
et al., 2017). Management of different diagnosis and treatment
of ccRCC is based on cancer progression. About 90% of patient
deaths are associated with cancer metastasis and invasion
(Campbell et al., 2017; Chaffer & Weinberg, 2011). Tumor
recurrence is still a high risk after nephrectomy for local‐regional
tumor patients (Ravaud et al., 2016). Timely detection and early
diagnosis is extremely important for the treatment management.
Thus, it will be important to elucidate the potential molecular
mechanisms underlying the occurrence and development of
ccRCC.
Obesity, diabetes, and atherosclerosis have been reported
to be risk factors for RCC (Hager, Mikuz, Kolbitsch, & Moser,
2008; Psutka et al., 2014), and renal cancer is considered as a
metabolic disease (Linehan, Srinivasan, & Schmidt, 2010; Sudar-
shan et al., 2013). A recent study of ccRCC showed that most
abnormal lipids were identified as cholesterol, cholesterol esters,
and neutral lipids (triglycerides; Saito et al., 2016). Fatty acids
(FA) are degraded through the β‐oxidation pathway in the
mitochondria. Free‐fatty acids were taken up by hepatocytes
and converted to triglycerides (TGs) in the liver, or combined
with cholesterol and stored in lipid droplets (LDs; Martin &
Parton, 2006; Millward et al., 2010). However, the molecular
mechanisms and significance of lipid metabolism abnormalities
remain elusive in ccRCC.
In humans, hydroxy acid oxidase 2 (HAO2) belongs 2‐hydroxy
acid oxidase genes family (HAO1, HAO2, and HAO3) and encode
peroxisomal proteins with 2‐hydroxy acid oxidase activity.
HAO2 is primarily expressed primarily in kidney and liver, and
exhibits a greatest enzymatically active for long chain 2‐hydroxyl
acidic substrate. HAO2 oxidizes L‐2‐hydroxy acid to ketoacids,
then ketoacids generates hydrogen peroxide. These processes
produce reactive oxygen species (ROS) and lead to cell damage
(Jones, Morrell, & Gould, 2000; Mates, Segura, Alonso, &
Marquez, 2008). HAO2 is showed downregulated in
TABLE 1 Correlation between HAO2 mRNA expression and
clinicopathological parameters of patients with ccRCC
Variables
HAO2 mRNA expression
Low
(n = 263)
High
(n = 262) χ2 p value
Status Alive 153 198
Dead 110 64 15.783 0.000
Age (years) < = 60 127 133
>60 136 129 0.321 0.601
Gender Male 196 144
Female 67 118 22.011 0.000
T stage T1 + T2 147 190
T3 + T4 116 72 15.783 0.000
N stage N0 +NX 250 260
N1 13 2 8.261 0.007
M stage M0 +MX 208 239
M1 55 23 15.276 0.000
Grade G1 + G2 104 141
G3 + G4 159 121 10.743 0.001
TNM stage I + II 133 186
III + IV 130 76 21.278 0.000
Abbreviations: ccRCC, clear cell renal cell carcinoma; HAO2, hydroxy acid
oxidase 2.
F IGURE 1 HAO2 expression in TCGA‐KIRC microarray datasets. The mRNA levels of HAO2 were compared in different clinicopathological
parameters: (a) cancer versus para‐cancer, (b) cancer versus paired para‐cancer, (c) sex, (d) T stage, (e) TNM stage, and (f) G stage. HAO2,
hydroxy acid oxidase 2; TCGA‐KIRC, The Cancer Genome Atlas kidney renal clear cell carcinoma. *p < .05, **p < .01, ***p < .001, and
****p < .0001, #### p < .0001. #, one‐way ANOVA; *, t test [Color figure can be viewed at wileyonlinelibrary.com]
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hepatocellular carcinoma (HCC) cancer tissues and overexpres-
sion HAO2 impaired HCC cells growth by increasing ROS
production and lipid peroxidation (Mattu et al., 2016). Never-
theless, as far as we know, the participation of HAO2 in ccRCC
has not been understood.
In this study, we investigated the expression of HAO2 with
clinicopathological features and patient survival in TCGA database.
Bioinformatics analysis and functional analysis explored the biologi-
cal role of HAO2 might be involved in ccRCC. Our study certificated
that HAO2 could be an antitumor gene and HAO2 inhibited
malignancy of ccRCC by promoting lipid catabolic process and by
eliminating lipid accumulation. These findings can serve as a basis for
the development of new prognostic markers and for better
therapeutic outcomes to ccRCC.
2 | MATERIALS AND METHODS
2.1 | Patient samples
Specimens of patients with ccRCC were get from the Department
of Urology, the First Affiliated Hospital of Xiamen University
between 2016 and 2018. The excised tissue was frozen into liquid
nitrogen immediately and stored at −80°C for further experiments.
Inform and obtain informed consent to approve the experimental
and research procedures from the Xiamen University Institutional
Review Board.
2.2 | RNA extraction and qRT‐PCR
The experiment procedure was performed as previously described
(Xiao, Wang, Wang, & Xing, 2019). Expression of HAO2 was
calculated with: 2−ΔCt (ΔCt = CtHAO2 −CtGAPDH). Primers were
purchased from GENEWIZ (GENEWIZ, Suzhou, China).
HAO2:
Forward 5′‐ TGACAGACTTTCAGGCCCAT‐3′;
Reverse 5′‐ CACTGATCTCCTCCCCTTGG‐3′,
GAPDH:
Forward 5′‐GAGTCAACGGATTTGGTCGT‐3′;
Reverse 5′‐GACAAGCTTCCCGTTCTCAG ‐3′.
2.3 | Cell culture and transient transfection
HK2, 786‐O, and A498 were obtained from The American Type
Culture Collection (ATCC) as 786‐O and A498 were came from
clear cell renal caner with VHL mutation (Brodaczewska, Szczylik,
Fiedorowicz, Porta, & Czarnecka, 2016; Sinha et al., 2017). Cancer
cells were cultured in high glucose Dulbecco's modified Eagle's
medium (DMEM) medium as previously described (Xiao et al.,
2019). The plasmid vectors containing Negative Control (NC) or
HAO2 (HAO2) were constructed by Genechem (Shanghai, China).
HAO2 and NC plasmids were transfected in 6‐well Plates with
Lipofectamine 2000 reagent (Invitrogen, Carlsbad) as previous
study (Xiao, Wang, Wang, & Xing, 2018).
F IGURE 2 Prognostic significance of HAO2 in TCGA‐KIRC. The HAO2 mRNA level was decreased and negatively correlated with (a) nonmetastasis
and distant metastasis, (b) nonlymph node metastasis and metastasis, (c) living status, (d) nonrecurrent and recurrent, (e) OS‐good and OS‐poor,
(F) DFS‐good and DFS‐poor. DFS, disease‐free survival; HAO2, hydroxy acid oxidase 2; OS, overall survival; TCGA‐KIRC, The Cancer Genome Atlas
kidney renal clear cell carcinoma. **p< .01, ***p< .001, and ****p< .0001 [Color figure can be viewed at wileyonlinelibrary.com]
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2.4 | Cell proliferation analysis
The A498 and 786‐O cells were transfected with NC or HAO2, and
added to the 96‐well plate with a density of 3 × 103/well. OD value
(cell proliferation rate) was detected by the Cell Counting Kit‐8
(CCK‐8; Dojindo Molecular Technologies, Rockville) at 450 nm as
previous study (Xiao et al., 2019).
2.5 | Migratory and invasion assays
Homogenizing cells without of plasma for 24 hr, then 2 x 105
or 1 x 105 cells were cultured in a 24‐well transwell plate with
or without Matrigel (Thermo Fisher Scientific, Waltham) coating
polycarbonate membrane inserts (Corning, NY) for invasion
or migratory assay. Incubation cells for 24 hr, then fixed
with 100% methanol, and stained with 0.05% crystal violet.
Observation cells under the microscope, five random regions
were counted.
2.6 | Western blot analysis and
immunohistochemistry (IHC)
Western blot analysis and IHC procedures carried out as previously
described (Xiao et al., 2019).
2.7 | Oil red O staining and triglycerides content
Cells were rinsed with phosphate‐buffered saline (PBS) and
fixed with 10% formaldehyde for 30 min. Then rinsed cells
with 60% isopropanol for 5 min, stained with 1 ml Oil Red O
(ORO; Wuhan Servicebio Technology, Wuhan, China) for
30 min. Triglycerides content was detected by using the
F IGURE 3 Correlation of HAO2 expression and overall survival (OS) in TCGA‐KIRC patients. (a) The correlation between HAO2
expression and OS of total patients with ccRCC was analyzed by Kaplan–Meier. (b)‐(k) Overall survival analysis towards the expression of
HAO2 was performed in subgroups of patients with ccRCC: (b) female, (c) male, (d) age ≤ 60 years, (e) age > 60 years, (f) T1 + T2 stage,
(g) N0 stage, (h) M0 stage, (i) M1 stage, (j) TNM III + IV stage, and (k) G3 + G4 stage. ccRCC, clear cell renal cell carcinoma; HAO2, hydroxy
acid oxidase 2; OS, overall survival; TCGA‐KIRC, The Cancer Genome Atlas kidney renal clear cell carcinoma. **p < .01, ***p < .001, and
****p < .0001 [Color figure can be viewed at wileyonlinelibrary.com]
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Triglycerides Assay Kit (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) according to manufacturer's
instructions.
2.8 | Bioinformatics analysis
The ccRCC patient clinical data used for univariate and
multivariate Cox proportional hazard regression (Goldman
et al., 2015) were obtained from The Cancer Genome
Atlas Kidney Clear Cell Carcinoma (TCGA‐KIRC) database.
Detailed clinical and molecular characteristics could be
found on the TCGA website (https://xenabrowser.net/heatmap/).
Overall survival (OS) and disease‐free survival (DFS) were the
primary endpoints of this study. OS was defined as the
time between diagnosis and death or was censored at the last
follow‐up. DFS was defined as the time between diagnosis or
surgery and the recurrence of disease or death (for any reason) at
the last follow‐up.
Gene set enrichment analysis (GSEA) studied the pathway
involved in ccRCC pathogenesis of HAO2 dependent on high
or low HAO2 in tumors (http://www.broadinstitute.org/gsea;
Subramanian et al., 2005) as previously described (Xiao et al.,
2019).
2.9 | Statistical analysis
The data were described by median and/or range, paired samples
were analyzed with paired sample t test, four group samples
were analyzed with one‐way analysis of variance (ANOVA; #),
two group with t test (*). Kaplan–Meier (KM) curve evaluated
survival rate with expression level of HAO2 with log‐rank test.
Short or long OS and DFS were discriminated as good ( ≥ 5 years,
living or disease‐free) or poor ( ≤ 2 years, die or recurred/
progressed). The p < .05 is statistically significant. All statistical
analyses were performed by SPSS Statistics 22.0 (IBM SPSS,
Chicago, IL).
F IGURE 4 Correlation of HAO2 expression and disease‐free survival (DFS) in TCGA‐KIRC patients. (a) The correlation between HAO2 expression
and DFS of total patients with ccRCCwas analyzed by Kaplan–Meier. (b)–(k) Overall survival analysis towards the expression of HAO2was performed in
subgroups of patients with ccRCC: (b) female, (c) male, (d) age≤60 years, (e) age >60 years, (f) T3 + T4 stage, (g) N0 stage, (h) M0 stage, (i) TNM III + IV
stage, (j) G1+G2 stage, and (k) G3+G4 stage. ccRCC, clear cell renal cell carcinoma; HAO2, hydroxy acid oxidase 2; TCGA‐KIRC, The Cancer Genome
Atlas kidney renal clear cell carcinoma. **p< .01, ***p< .001, and ****p< .0001 [Color figure can be viewed at wileyonlinelibrary.com]
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3 | RESULTS
3.1 | Clinical and molecular characteristics of the
patients with HAO2
To investigate the expression and development role of HAO2 in
ccRCC, we investigated the mRNA expression in TCGA database,
detailed clinical pathological information was presented in
Table 1. HAO2 mRNA expression was significantly lower in
ccRCC cancer tissues when compared with corresponding
noncancerous normal tissues (Figure 1a). Similarly results
showed in 72 paired tissues (Figure 1b). Statistical analysis
showed a significant association between low HAO2 expression
and male patients (Figure 1c), advanced tumor stage (T stage;
TABLE 2 Univariate and multivariate analyses of HAO2 mRNA level and patient overall survival
Univariate analysis Multivariate analysisc
Variable HRa 95% CIb p HR 95% CI p
Overall survival
Age (years)
≤ 60 vs. > 60 1.758 1.294–2.388 .000 1.65 1.209–2.253 .002
Sex
Female vs. male 0.943 0.693–1.284 .825
T stage
T3 or T4 vs. T1 or T2 3.12 2.306–4.220 .000 1.627 1.138–2.326 .008
N stage
N1 vs. N0 or NX 3.917 2.121–7.234 .000 2.054 1.084–3.890 .027
M stage
M1 vs. M0 or MX 4.303 3.155–5.868 .000 2.589 1.809–3.705 .000
Grade
G3 or G4 vs. G1 or G2 2.613 1.865–3.661 .000 1.693 1.180–2.431 .004
HAO2
High vs. Low 0.5 0.368–0.681 .000 0.642 0.465–0.887 .007
Abbreviation: HAO2, hydroxy acid oxidase 2.
aHazard ratio, estimated from Cox proportional hazard regression model.
bConfidence interval of the estimated HR.
cMultivariate models were adjusted for T, N, M classification, age, and gender.
TABLE 3 Univariate and multivariate analyses of HAO2 mRNA level and patient disease‐free survival
Univariate analysis Multivariate analysis
Variable HRa 95% CIb p HR 95% CI p
Disease‐free survival
Age (years)
≤ 60 vs. > 60 1.358 0.954–1.935 .090
Sex
Female vs. male 1.425 0.959–2.118 .079
T stage
T3 or T4 vs. T1 or T2 4.601 3.185–6.646 .000 2.006 1.314–3.063 .001
N stage
N1 vs. N0 or NX 5.991 3.008–11.933 .000 3.310 1.589–6.895 .001
M stage
M1 vs. M0 or MX 8.627 5.943–12.522 .000 4.890 3.212–7.443 .000
Grade
G3 or G4 vs. G1 or G2 3.453 2.287–5.214 .000 2.339 1.523–3.592 .000
HAO2
High vs. Low 0.451 0.311–0.654 .000 0.671 0.455–0.990 .044
Abbreviation: HAO2, hydroxy acid oxidase 2.
aHazard ratio, estimated from Cox proportional hazard regression model.
bConfidence interval of the estimated HR.
cMultivariate models were adjusted for T, N, M classification, age, and gender.
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Figure 1d), TNM stages (Figure 1e), and grade (Figure 1f), but no
significant differences in age. CcRCC was associated with
function loss of von Hippel‐Lindau tumor suppressor (VHL), but
there is no significant correlation between VHL and HAO2
(Figure S1).
3.2 | Prognostic significance of HAO2 in ccRCC
According to the median expression levels of HAO2, all patients were
divided into two groups, then we explored the prognostic role of
HAO2 in ccRCC. Statistical analysis showed that HAO2 expression
F IGURE 5 HAO2 expression in ccRCC tissues and cells. HAO2 is downregulated in ccRCC tissues and cancer cells. (a) and (b) Gene
expression levels of HAO2 in renal cancer cell lines. (c) and (d) qRT‐PCR analysis of HAO2 mRNA expression in ccRCC tissues and
para‐cancer tissues. (e) IHC analysis of HAO2 protein expression in ccRCC tissues and para‐cancer tissues. ccRCC, clear cell renal
cell carcinoma; HAO2, hydroxy acid oxidase 2; IHC, immunohistochemistry; qRT‐PCR, quantitative real‐time polymerase chain reaction.
**p < .01 and ***p < .001 [Color figure can be viewed at wileyonlinelibrary.com]
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was lower in patients with distant metastasis and lymph node
metastasis (Figure 2a,b). HAO2 was significantly lower in dead and
recurrence patients (Figure 2c,d). Moreover, HAO2 was able to classify
prognosis of OS and DFS in ccRCC (Figure 2e,f).
3.3 | Correlation of HAO2 expression and overall
survival in ccRCC
Kaplan‐Meier survival analysis was used to determine the
correlation of HAO2 expression and OS in patients with ccRCC.
Low HAO2 expression patients exhibited shorter OS time
(Figure 3a). Various subgroups OS analysis of patients with
ccRCC having HAO2 manifested that HAO2 expression could be
a potential prognostic factor for patients with ccRCC in
subgroups, including sex (Figure 3b,c), age (Figure 3d,e), T3 + T4
stage (Figure 3f), and N0 stage (Figure 3g). M0 and M1 stage
(Figure 3h,i), TNM III + IV stage (Figure 3j), and G3 + G4 stage
(Figure 3k).
3.4 | Correlation of HAO2 expression and
disease‐free survival in ccRCC
Kaplan–Meier survival analysis determined low HAO2 expression
patients exhibited shorter DFS time (Figure 4a). Similarly, the
results manifested that HAO2 could be a potential prognostic
factor in ccRCC subgroups, including sex (Figure 4b,c), age
(Figure 4d,e), T1 + T2 stage (Figure 4f), N0 stage (Figure 4g),
M0 stage (Figure 4h), TNM I + II stage (Figure 4i), G1 + G2
(Figure 4j), and G3 + G4 (Figure 4k).
3.5 | Univariate and multivariate analyses of OS
and DFS in ccRCC
Multivariate analysis showed that older age ( > 60 years; HR,
1.650; p = 0.002), T3 + T4 stage (HR, 1.627; p = 0.008), N1 stage
(HR, 2.054; p = 0.027), M1 stage (HR, 2.589; p = 0.000), G3 + G4
(HR, 1.693; p = 0.004), and high HAO2 expression (HR, 0.642;
p = 0.007) could be considered as independent prognostic
indicators of OS (Table 2). Meanwhile, multivariate analysis
demonstrated that T3 + T4 stage (HR, 2.006; p = 0.001), N1 stage
(HR, 3.310; p = 0.001), M1 stage (HR, 3.212; p = 0.000), G3 + G4
(HR, 2.239; p = 0.000), and high HAO2 expression (HR, 0.671;
p = 0.044) could be considered as independent prognostic
indicators of DFS (Table 3). Univariate and multivariate analyses
assessed HAO2 could be an outstanding independent prognostic
indicators of OS and DFS in ccRCC.
3.6 | HAO2 expression in ccRCC tissues and cancer
cells
As HAO2 was downregulated in TCGA‐KIRC, we confirmed HAO2 was
downregulated in RCC cells with qRT‐PCR and western blot analysis
(Figure 5a,b). We also showed the HAO2 expression in ccRCC patient
samples was lower by qRT‐PCR and IHC (Figure 5c–e), detailed
clinicopathological information was presented in Table 4. These results
certificated that HAO2 level was significantly lower in RCC cells and
cancer tissues.
3.7 | HAO2 promotes lipid catabolic process in ccRCC
As ccRCC is a metabolic disease, tumor tissue is vacuolated with
hematoxylin and eosin (H&E) staining and lipid accumulation with
Oil Red O (ORO) staining (Figure 6a). We explored the biological
signaling of HAO2 might be involved in ccRCC pathogenesis with
GSEA. GSEA results performed that HAO2 expression was
associated with neutral lipid catabolic process, metabolic pro-
cess, and lipid oxidation (Figure 6b). The mRNA and protein
expression of HAO2 expression were tested in 786‐O and A498
cells after transfected with plasmid vectors with HAO2 (HAO2)
or negative control (NC; Figure 6c,d). HAO2 overexpression
eliminated lipid droplet accumulation by ORO staining (Figure 6e)
and triglycerides (Figure 6f).
3.8 | Biological function of HAO2 in renal cancer
cells
As HAO2 could eliminated lipid droplet accumulation and
triglycerides, then we detected the biological function of HAO2.
TABLE 4 Clinicopathological parameters of 24 patients with
ccRCC
Variables
Validation set
24 Pairs of ccRCC and adjacent
normal tissues
Age (years mean) 54
Gender (no.) male and
female
24
Pathological T stage no.
T1 10
T2 4
T3 9
T4 1
Pathological N stage no.
N0 23
N1 1
Pathological M stage no.
M0 23
M1 1
Pathological grade no.
G1 3
G2 17
G3 4
G4
AJCC TNM stage no.
I 10
II 4
III 9
VI 1
Abbreviation: ccRCC, clear cell renal cell carcinoma.
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F IGURE 6 HAO2 promotes lipid catabolic process in ccRCC. (a) H&E and ORO staining compared normal and cancer tissues. (b) GSEA
enrichment curves are shown for activated gene sets related to neutral lipid catabolic process, metabolic process, and lipid oxidation in TCGA
database. (c) and (d) HAO2 mRNA and protein expression after overexpression. (e) and (f) HAO2 overexpression eliminated lipid droplet
accumulation and triglycerides. H&E, hematoxylin and eosin staining; HAO2, hydroxy acid oxidase 2; GSEA, Gene set enrichment analysis;
ORO, Oil Red O staining [Color figure can be viewed at wileyonlinelibrary.com]
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GSEA results performed that HAO2 was associated with the gene
signatures of epithelial–mesenchymal transition (EMT), G2M
checkpoint, and Kirsten rat sarcoma viral oncogene (KRAS)
signaling (Figure 7a). Overexpression of HAO2 significantly
repressed the KRAS expression (Figure 7b), the proliferation
when compared with the NC group (Figure 7c,d), furthermore, the
migration and invasion ability of 786‐O and A498 cells was
significantly inhibited in transfected with HAO2 compared with
NC (Figure 7e,f).
4 | DISCUSSION
This study reported the expression of HAO2 in the clinical significance of
ccRCC and found: (1) HAO2 exhibited low expression in ccRCC and RCC
cells; (2) low HAO2 expression was associated with living status, T stage,
N stage, M stage, TNM stages, and grade; (3) HAO2 was an independent
predictor of prognostic of OS and DFS in TCGA‐KIRC database; (4) high
HAO2 was associated with gene set in neutral lipid catabolic process,
metabolic process, lipid oxidation with GSEA, and overexpression of
HAO2 promoted lipid catabolic process and eliminated triglycerides; and
(5) low HAO2 was associated with gene set in EMT, G2M checkpoint,
and KRAS signaling. HAO2 overexpression suppressed cell migration,
invasion, and proliferation capability, and KRAS expression in 786‐O and
A498 cells.
Fundamentally, ccRCC is considered as a metabolic disease and
cholesterol, cholesterol esters, and neutral lipids are the most
abnormal accumulation lipid in cancer tissues (Saito et al., 2016;
Zhang et al., 2017). Previous studies have shown that these abnormal
lipids play a critical role in the progression of ccRCC. Therefore,
identifying genes that regulate abnormal lipid metabolism in ccRCC is
urgently needed.
2‐Hydroxy acid oxidase genes family contains three members:
HAO1, HAO2, and HAO3. The RNA datasets of TCGA‐KIRC
F IGURE 7 Biological function of HAO2 in renal cancer cells. (a) GSEA enrichment curves are shown for activated gene sets related to EMT,
G2M checkpoint, and KRAS signaling in TCGA database. (b) KRAS expression was successfully overexpressed in 786‐O and A498 cells. (c) and
(d) Cell counting kit‐8 assays detected the effects of HAO2 overexpression on proliferation of 786‐O and A498 cells. Representative images of
migration and invasion assays performed using 786‐O and A498 cells (e) and (f). Data are presented as the means ± standard deviation from
three independent experiments. EMT, epithelial–mesenchymal transition; HAO2, hydroxy acid oxidase 2; GSEA, Gene set enrichment analysis;
KRAS, Kirsten rat sarcoma viral oncogene. *p < .05, **p < .01, and ***p < .001 [Color figure can be viewed at wileyonlinelibrary.com]
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database include HAO1 and HAO2, and there is no different
expression between ccRCC tissues and noncancerous normal tissues
of HAO1 (data not show). HAO2 is primarily expressed primarily in
kidney and liver, and exhibits a greatest enzymatically active for long
chain 2‐hydroxyl acidic substrate. HAO2 oxidants L‐2‐hydroxy acids
to ketoacids, then ketoacids generates hydrogen peroxide. These
processes produce ROS and ultimately promote cell damage (Jones
et al., 2000; Mates et al., 2008). HAO2 is downregulated in HCC and
exogenous expression inhibits HCC tumorigenic ability by increasing
ROS production and lipid peroxidation (Mattu et al., 2016).
ccRCC is associated with function loss of VHL and leads to
hypoxia‐inducible transcription factor (HIF) accumulation (Keith,
Johnson, & Simon, 2011; Metelo, Noonan, & Iliopoulos, 2015). HIF2α
promotes expression of perilipin2, a characterized as lipid droplet
(LD) protein, leading to lipid storage and cell viability in ccRCC (Qiu
et al., 2015). Repression of fatty acid metabolism drives lipid
deposition and ccRCC tumor progress (Du et al., 2017). But we
found no correlation between VHL and HAO2 in our study.
At the moment, no literature reporting the reasons for HAO2
reduction and the specific mechanism of action in ccRCC. Cancer
progression by conferring a more motility and aggressive phenotype
on cancer cells is a key foundation for EMT (Beerling et al., 2016;
Chaffer, San Juan, Lim, & Weinberg, 2016). GSEA demonstrated that
low HAO2 was associated with gene set of neutral lipid catabolic
process, metabolic process, and lipid oxidation in TCGA‐KIRC
database, it may be hypothesized that HAO2 could eliminate lipid
droplet accumulation of ccRCC. HAO2 was also demonstrated
associating with the gene signatures of EMT, G2M checkpoint, and
KRAS signaling by GSEA, it revealed that HAO2 could positively
negatively regulate EMT, control cell cycle progression in ccRCC.
Overexpression of HAO2 significantly could repress KRAS expres-
sion, proliferation, the migration, and invasion ability of ccRCC
cancer cells in vitro.
This study is first to demonstrate the prognostic role and
probable mechanism of HAO2 in ccRCC. These results demonstrate
that HAO2 can be used as a potential novel biomarker for predicting
prognosis of ccRCC. HAO2 could eliminate lipid droplet accumulation
and promote lipid catabolic process in ccRCC, inhibit EMT, and KRAS
expression. However, the detailed mechanism of how HAO2
eliminate lipid droplet accumulation or inhibit KRAS expression does
not investigated in ccRCC cancer cells. All these studies provided
clues to help understanding the prognostic role and probable
mechanism of HAO2 in ccRCC and suggested HAO2 may be a novel
therapeutic target for manipulating of patients with ccRCC.
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